A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis

Published:2018-01 Issue:1 Volume:197 Page:94-103
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Parker Joseph M.¹,Glaspole Ian N.²³,Lancaster Lisa H.⁴,Haddad Tarik J.⁵,She Dewei⁶,Roseti Stephanie L.¹,Fiening Jon P.⁷,Grant Ethan P.⁸,Kell Chris M.⁹,Flaherty Kevin R.¹⁰

Affiliation:

1. Clinical Development

2. Department of General Respiratory Medicine and Lung Transplantation, The Alfred Hospital, Melbourne, Australia

3. Department of Medicine, Monash University, Melbourne, Australia

4. Allergy, Pulmonary, and Critical Care, Vanderbilt University, Nashville, Tennessee

5. Pulmonary and Critical Care Medicine, Tampa General Hospital, Tampa, Florida

6. Clinical Biostatistics and Data Management

7. Clinical Operations, and

8. Translational Medicine, MedImmune, Gaithersburg, Maryland

9. Product Development, MedImmune, Cambridge, United Kingdom; and

10. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

http://www.atsjournals.org/doi/pdf/10.1164/rccm.201704-0784OC

Reference25 articles.

1. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

2. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

3. Hot off the breath: a big step forward for idiopathic pulmonary fibrosis

4. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis;Pharmaceutical Science Advances;2024-12

2. IL-4-induced SOX9 confers lineage plasticity to aged adult lung stem cells;Cell Reports;2024-08

3. Evidence from recent clinical trials in fibrotic interstitial lung diseases;Current Opinion in Pulmonary Medicine;2024-07-04

4. Immune mechanisms in fibrotic interstitial lung disease;Cell;2024-07

5. The current landscape of antifibrotic therapy across different organs: A systematic approach;Pharmacological Research;2024-07